This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013;20(12):850-60.

doi: 10.5551/jat.19166. Epub 2013 Dec 10.

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version

Tamio Teramoto¹, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode, Koutaro Yokote

Affiliations

PMID: 24335039
DOI: 10.5551/jat.19166

Free article

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version

Tamio Teramoto et al. J Atheroscler Thromb. 2013.

Free article

. 2013;20(12):850-60.

doi: 10.5551/jat.19166. Epub 2013 Dec 10.

Authors

Tamio Teramoto¹, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode, Koutaro Yokote

Affiliation

¹ Committee for Epidemiology and Clinical Management of Atherosclerosis.

PMID: 24335039
DOI: 10.5551/jat.19166

No abstract available

PubMed Disclaimer

Similar articles

Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Teramoto T, et al. J Atheroscler Thromb. 2013;20(12):835-49. doi: 10.5551/jat.18820. Epub 2013 Oct 29. J Atheroscler Thromb. 2013. PMID: 24172256 No abstract available.
Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society Committee for Epidemiology and Clinical Management of Atherosclerosis. Teramoto T, et al. J Atheroscler Thromb. 2014;21(4):291-5. doi: 10.5551/jat.19711. Epub 2013 Dec 10. J Atheroscler Thromb. 2014. PMID: 24335044 No abstract available.
Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.
Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society (JAS). Teramoto T, et al. J Atheroscler Thromb. 2013;20(7):603-15. doi: 10.5551/jat.15867. Epub 2013 Jul 25. J Atheroscler Thromb. 2013. PMID: 23883545 No abstract available.
Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.
Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M. Teramoto T, et al. J Atheroscler Thromb. 2007 Apr;14(2):45-50. doi: 10.5551/jat.14.45. J Atheroscler Thromb. 2007. PMID: 17485887 Review. No abstract available.
Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese.
Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M. Teramoto T, et al. J Atheroscler Thromb. 2007 Dec;14(6):267-77. doi: 10.5551/jat.e578. J Atheroscler Thromb. 2007. PMID: 18176013 Review. No abstract available.

See all similar articles

Cited by

Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
Yamashita S, Masuda D, Ohama T, Arai H, Bujo H, Kagimura T, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y; PROSPECTIVE Study Group. Yamashita S, et al. J Atheroscler Thromb. 2016 Jun 1;23(6):746-56. doi: 10.5551/jat.32813. Epub 2016 Jan 22. J Atheroscler Thromb. 2016. PMID: 26803913 Free PMC article. Clinical Trial.
Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.
Tanaka A, Inaguma D, Watanabe Y, Ito E, Kamegai N, Shimogushi H, Shinjo H, Koike K, Otsuka Y, Takeda A. Tanaka A, et al. Intern Med. 2017;56(12):1531-1535. doi: 10.2169/internalmedicine.56.7958. Epub 2017 Jun 15. Intern Med. 2017. PMID: 28626179 Free PMC article.
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T, Kondo A, Kiyosue A, Harada-Shiba M, Ishigaki Y, Tobita K, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. Teramoto T, et al. Lipids Health Dis. 2017 Jun 17;16(1):121. doi: 10.1186/s12944-017-0513-7. Lipids Health Dis. 2017. PMID: 28623954 Free PMC article. Clinical Trial.
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.
Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. Jacobson TA, et al. Patient. 2017 Jun;10(3):321-334. doi: 10.1007/s40271-016-0211-y. Patient. 2017. PMID: 27981439 Free PMC article.
Statin use and all-cause and cancer mortality: BioBank Japan cohort.
Yokomichi H, Nagai A, Hirata M, Tamakoshi A, Kiyohara Y, Kamatani Y, Muto K, Ninomiya T, Matsuda K, Kubo M, Nakamura Y; BioBank Japan Cooperative Hospital Group; Yamagata Z. Yokomichi H, et al. J Epidemiol. 2017 Mar;27(3S):S84-S91. doi: 10.1016/j.je.2016.12.011. Epub 2017 Feb 11. J Epidemiol. 2017. PMID: 28196737 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information